Best Weight Loss Injections for Women in 2026 — Ranked & Reviewed
The GLP-1 medications themselves are the same for everyone — semaglutide and tirzepatide are not gender-specific — but the programs around them differ. Women lose weight on GLP-1s at equal or slightly higher rates than men in trial data, and considerations like PCOS, perimenopause, birth-control interactions with tirzepatide, and pregnancy planning genuinely change which provider fits. This list ranks injectable GLP-1 providers with women's-health depth: menopause-certified clinicians, PCOS-aware programs, and platforms built around women's care.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Quick Picks: Top 5
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
Embody
Verified partnerBest for: lowest first-month entry pricing on compounded GLP-1s
Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
Score Breakdown
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Found
Verified partnerBest for: mainstream telehealth GLP-1 access
Personalized weight care platform with a self-pay membership model plus medication costs.
Score Breakdown
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
MEDVi
Verified partnerBest for: patients who want the option to switch between compounded and brand-name GLP-1 through one provider
MEDVi is a telehealth weight-loss platform offering compounded GLP-1 injections and tablets (semaglutide) as well as brand-name Wegovy and Zepbound through licensed US pharmacies. Medical treatment is delivered by OpenLoop Health clinicians and CareGLP Affiliated P.C.s.
Score Breakdown
Pros
- ✓Both compounded and brand-name (Wegovy, Zepbound) GLP-1 options in one platform
- ✓Oral tablet and injectable formats
- ✓Named US pharmacy partners (Triad Rx, Precision Medicine, RedRock Pharmacy, Beaker Pharmacy & Compounding)
- ✓Clinical oversight through OpenLoop Health provider network and CareGLP Affiliated P.C.s
- ✓Direct-to-home shipping with 24/7 support
Cons
- ✗Refill price for compounded GLP-1 injection ($299) steps up significantly from $179 first-month offer
- ✗Not available in Mississippi or North Dakota (telehealth regulation constraints)
- ✗Alabama and California patients can only receive injectable formats, not tablets, per state law
- ✗Kansas, Indiana, New Mexico, Oklahoma, and West Virginia require a synchronous provider visit before prescribing
- ✗No LegitScript or PCAB certification disclosed on the site
Mochi Health
Best for: budget-conscious shoppers
Obesity medicine telehealth provider offering aggressively priced compounded GLP-1 programs.
Score Breakdown
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Hers
Best for: mainstream telehealth GLP-1 access
Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.
Score Breakdown
Pros
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
How to choose a GLP-1 provider as a woman
The medication is the same regardless of sex — but the care around it isn't. For women, the provider's depth on hormonal health, PCOS, menopause, and pregnancy planning is what separates a good fit from a generic one.
What to look for
- Hormonal-health expertise. PCOS and perimenopause both affect weight and how you respond to a GLP-1. Providers with menopause-certified clinicians or PCOS-aware programs can tailor care in ways a one-size telehealth intake can't.
- Contraception and pregnancy screening. Tirzepatide can reduce the effectiveness of oral birth control, and GLP-1s must be stopped before pregnancy. A good provider screens for this up front — not as an afterthought.
- Muscle-preserving support. Rapid loss risks lean mass. Look for providers that emphasize protein targets and resistance training alongside the medication, so you lose fat, not muscle.
Red flags to avoid
- No named pharmacy or LegitScript listing. A legitimate compounded-GLP-1 provider names its 503A/503B pharmacy partner and carries LegitScript certification. If neither is disclosed, you can't verify what you're injecting.
- Async-only, no real clinician review. A prescriber should review your intake and be reachable for dose questions. Instant approval with no way to reach a clinician is a safety gap.
- Teaser pricing that hides the real cost. A low 'first month' price that jumps at higher doses, or a membership fee stacked on top of the medication, can double the true monthly total. Confirm the ongoing, all-in price before you pay.
- Weight-loss claims for B12, MIC, or HCG shots. Only GLP-1 injections have trial evidence for weight loss. A clinic selling B12, lipotropic, or HCG shots as a weight-loss treatment is a red flag.
Every provider ranked above is scored against these criteria across our six-dimension methodology, and prices are re-verified against each provider’s live site.
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Related Rankings
Frequently Asked Questions
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.